答是美联合复方左旋多巴治疗帕金森病的疗效观察  

Enhaced Efficacy of Combination of Tolcapone and Levodopa/ Decarboxylase Inhibitor in Treating Parkinsonian Patients

作　　者：翁中芳[1] 王瑛[1] 肖勤[1] 刘振国[1] 王增[1] 陈生弟[1] 

机构地区：[1]上海第二医科大学瑞金医院神经科,帕金森病诊疗与研究中心,上海200025

出　　处：《上海第二医科大学学报》2000年第3期252-254,共3页Acta Universitatis Medicinalis Secondae Shanghai

摘　　要：目的研究复方左旋多巴联合答是美治疗 30例帕金森病的疗效及安全性。　方法采用开放性自身对照研究方法 ,并以改良的Webster、试行的UPDRS评分标准及病人日记进行观察。　结果与单用复方左旋多巴比较 ,加用答是美治疗 6周后 ,“开”期潜伏期缩短 2 6 .3min ,“开”期持续时间增加 2 .9h ,平均总有效率为 6 0 .0 % ,结果有非常显著性差异 ,不良反应轻微而少见。Objective To observe the efficacy and safety by the use of Tolcapone puls levodopa/decarboxylase inhibitor(DDC-I) during treatment 30 patients with Parkinson's disease. Methods Every patient with Parkinson's disease was evaluated by using two rating scales of modified Webster and UPDRS and patient's diary. Results Addition of Tolcapone (average dosage was 371 mg/d) for six weeks showed that the attack of response shortened to 26.3min, on' time lasted 2.9hr, and the ave rage rate of total improvement was 60.0%, as compared with levodopa/DDC-I alone. The significant difference was seen as those mentioned above. Untoward effect was mild or not observed. Conclusion The present study indicated that tolcapone is a new anti-parkinsonian drug with not only good efficacy but also well tolerability.\;

关 键 词：答是美 联合用药 震颤性麻痹 复方左旋多巴 

分 类 号：R742.5[医药卫生—神经病学与精神病学]